Welcome to our dedicated page for Zura Bio news (Ticker: ZURA), a resource for investors and traders seeking the latest updates and insights on Zura Bio stock.
Zura Bio Limited reports news on its clinical-stage immunology pipeline for autoimmune and inflammatory diseases. The company develops dual-pathway antibody candidates, led by tibulizumab (ZB-106), which targets IL-17A and BAFF and is being evaluated in Phase 2 studies for hidradenitis suppurativa and systemic sclerosis. Its additional clinical-stage candidates include crebankitug (ZB-168), targeting IL-7R, and torudokimab (ZB-880), targeting IL-33.
Recurring updates cover clinical study designs and presentations, financial results, corporate presentations, leadership and board changes, equity incentive grants, and capital-raising activity involving Class A ordinary shares and pre-funded warrants.
Zura Bio Limited, a clinical-stage biotechnology company focused on immunology, has completed its business combination with JATT Acquisition Corp. The merger, approved by JATT's shareholders on March 16, 2023, results in approximately $65 million in gross cash proceeds to support R&D initiatives and potential acquisitions. The combined entity will trade under the ticker symbol ZURA on Nasdaq starting March 21, 2023. The funds will be used for the clinical development of Zura's pipeline candidates, ZB-168 and torudokimab, with leadership from former Arena Pharmaceuticals executives. This milestone aims to enhance the company's immunology portfolio.